The Drug-Induced Respiratory Disease Website and App

Status post-hematopoietic stem cell (HSCT) or bone marrow transplantation (BMT)

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.b

Pulmonary arterial hypertension

Publications

Nakaoka H, Sakata Y, Yamamoto M, Maeda T, Arita Y, Shioyama W, Nakaoka Y, Kanakura Y, Yamashita S, Komuro I, Yamauchi-Takihara K

Pulmonary hypertension associated with bone marrow transplantation.

Journal of cardiology cases. 2010;2(1):e23-e27

Jodele S, Hirsch R, Laskin B, Davies S, Witte D, Chima R

Pulmonary arterial hypertension in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013;19(2):202-7

Steward CG, Pellier I, Mahajan A, Ashworth MT, Stuart AG, Fasth A, Lang D, Fischer A, Friedrich W, Schulz AS, Working Party on Inborn Errors of the European Blood and Marrow Transplantation Group

Severe pulmonary hypertension: a frequent complication of stem cell transplantation for malignant infantile osteopetrosis.

British journal of haematology. 2004;124(1):63-71